The European Medicines Agency has recommended the refusal of the marketing authorisation for Turalio, a medicine intended for the treatment of tenosynovial giant cell tumour.
The Agency issued its opinion on 25 June 2020. The company that applied for authorisation, Daiichi Sankyo Europe GmbH, may ask for re-examination of the opinion within 15 days of receiving the opinion.
Questions and answers on the refusal of the marketing authorisation for Turalio (pexidartinib) (PDF/107.92 KB)Adopted
First published: 26/06/2020
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Daiichi Sankyo Europe GmbH
|Date of opinion||
|Date of refusal of marketing authorisation||